Hao Wang

Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine

F. Gao, Jinghua Yan, Junjie Xu, 2022, bioRxiv.

Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.

M. R. Capeding, G. Dayan, B. Zambrano, 2022, The Lancet. Infectious diseases.

Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.

C. Diazgranados, M. R. Capeding, G. Dayan, 2020, The Lancet. Infectious diseases.

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.

C. Diazgranados, G. Dayan, R. Forrat, 2022, The Lancet. Microbe.

Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials

C. Diazgranados, G. Dayan, R. Forrat, 2020, The Lancet. Infectious diseases.

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

L. Shek, C. Frago, A. Bouckenooghe, 2021, Human vaccines & immunotherapeutics.

Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4–5 Years Earlier in Latin America

C. Diazgranados, R. Dietze, G. Dayan, 2020, The Pediatric infectious disease journal.